Standard Operating Procedure for Development of Test Procedures for Active Pharmaceutical Ingredients (API)
Department | Analytical Method Development |
---|---|
SOP No. | SOP/AMD/006/2025 |
Supersedes | SOP/AMD/006/2022 |
Page No. | Page 1 of 15 |
Issue Date | 19/05/2025 |
Effective Date | 20/05/2025 |
Review Date | 19/05/2026 |
1. Purpose
This SOP defines the systematic process for developing test procedures for active pharmaceutical ingredients (API), ensuring that all analytical methods are scientifically justified, robust, and aligned with ICH
2. Scope
This SOP applies to the Analytical Method Development (AMD) team responsible for establishing test procedures including identification, assay, related substances, residual solvents, and physicochemical tests for APIs used in research, development, and commercial batches.
3. Responsibilities
- AMD Scientist: Designs and performs method development experiments based on literature review and API properties.
- Team Leader: Reviews developmental data and approves optimized test parameters.
- QA Department: Verifies adherence to protocol and documentation standards.
- Head – AMD: Provides final authorization for the developed test procedure.
4. Accountability
The Head of Analytical Method Development is accountable for ensuring that all API test procedures are scientifically sound, documented properly, and validated according to applicable regulatory guidelines.
5. Procedure
5.1 Understanding the API Profile
- Collect the following data for the API:
- Chemical structure, molecular weight
- pKa, solubility, and logP
- UV absorption, stability profile
- Impurity profile and known degradants
- Record API attributes in Annexure-1: API Profile Sheet.
5.2 Literature and Regulatory Review
- Review literature, pharmacopoeias (USP, IP, BP), and previously validated methods.
- Summarize existing analytical techniques, conditions, and parameters for similar molecules.
- Document findings in Annexure-2: Reference Summary Log.
5.3 Experimental Design for Method Development
- Design method development experiments based on:
- Chromatographic technique (e.g., HPLC, GC)
- Sample and standard preparation procedures
- Selection of mobile phase, column, and detection wavelength
- Ensure evaluation of peak purity, resolution, retention time, tailing factor, and plate count.
5.4 Optimization of Test Parameters
- Optimize based on system suitability and robustness:
- Buffer pH, ionic strength, gradient programs
- Injection volume and flow rate
- Detection wavelength
- Document optimized parameters in Annexure-3: Method Optimization Log.
5.5 Drafting of Test Procedure
- Prepare draft test procedure covering:
- Purpose
- Scope
- Principle of method
- Equipment and chemicals required
- System suitability criteria
- Stepwise procedure for standard and sample preparation
- Calculation formula
- Use Annexure-4: Draft Test Format for initial documentation.
5.6 Internal Review and Approval
- Submit the draft to the AMD Team Lead for review.
- Incorporate corrections and finalize the document.
- Obtain QA review and Head – AMD approval before use.
5.7 Method Transfer and Validation Readiness
- Once approved, initiate method transfer to Quality Control (QC) for verification or validation.
- Ensure validation protocols are aligned with ICH Q2 requirements (specificity, precision, linearity, range, accuracy, robustness, LOD, LOQ).
5.8 Documentation and Archival
- Store final version of the test procedure in the AMD document control system.
- Ensure backups are maintained and version history is traceable.
- File supporting development data with traceable links to project ID and molecule name.
6. Abbreviations
- API: Active Pharmaceutical Ingredient
- AMD: Analytical Method Development
- LOD: Limit of Detection
- LOQ: Limit of Quantitation
- HPLC: High-Performance Liquid Chromatography
- QA: Quality Assurance
- QC: Quality Control
7. Documents
- API Profile Sheet – Annexure-1
- Reference Summary Log – Annexure-2
- Method Optimization Log – Annexure-3
- Draft Test Format – Annexure-4
8. References
- ICH Q2(R1) – Validation of Analytical Procedures
- Pharmacopoeial Standards (USP, IP, BP)
- WHO GMP Guidelines
9. SOP Version
Version: 2.0
10. Approval Section
Prepared By | Checked By | Approved By | |
---|---|---|---|
Signature | |||
Date | |||
Name | |||
Designation | |||
Department |
11. Annexures
Annexure-1: API Profile Sheet
API Name | Molecular Weight | Solubility | pKa | LogP |
---|---|---|---|---|
Metformin HCl | 165.63 | Water soluble | 12.4 | -1.43 |
Annexure-2: Reference Summary Log
Source | Title | Year | Reviewed By |
---|---|---|---|
USP 43 | Metformin Monograph | 2022 | Sunita Reddy |
PubMed | HPLC Method for Metformin Impurity Profiling | 2021 | Rajesh Kumar |
Annexure-3: Method Optimization Log
Date | Parameter Adjusted | Final Value | Observed Effect | Performed By |
---|---|---|---|---|
11/04/2025 | Flow Rate | 1.0 mL/min | Improved resolution | Ajay Mehra |
Annexure-4: Draft Test Format
Section | Description |
---|---|
System Suitability | RSD of standard injections ≤ 2%, resolution between peaks ≥ 2.0 |
Sample Preparation | Dissolve 100 mg in 100 mL diluent, filter, inject 10 µL |
Calculation | % Assay = (Sample area / Standard area) × Std weight / Sample weight × 100 |
Revision History:
Revision Date | Revision No. | Details | Reason | Approved By |
---|---|---|---|---|
04/05/2025 | 2.0 | Expanded method documentation and optimization log format | Audit observation |